TP53 and neoplasm: The demonstrated efficacy of targeting MDM4 to reactivate wt p53 tumor suppressive activity (Karni-Schmidt et al., 2016) has provided a strong rationale for therapeutic targeting MDM4 in this context, and multiple new approaches are being explored (as discussed in Section ‘MDM4 therapeutics and as a prognostic biomarker’).